DiaMedica Therapeutics Inc. (NASDAQ: DMAC) has dosed the first two patients in an investigator-sponsored Phase 2 trial evaluating DM199 (rinvecalinase ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE